Mesna is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis, among other approved uses. It is available as injection and tablets for intravenous and oral use. MedsAcross supplies Mesna for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. MESNEX is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
Source: US FDA prescribing information
Mesna reacts chemically with the urotoxic ifosfamide metabolites, acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. The first step in the detoxification process is the binding of mesna to 4-hydroxy-ifosfamide forming a non-urotoxic 4-sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic metabolites and inhibits their effects on the bladder.
Source: US FDA prescribing information
MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections or a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below. The dosing schedule should be repeated on each day that ifosfamide is administered. When the dosage of ifosfamide is adjusted, the ratio of MESNEX to ifosfamide should be maintained. Intravenous Dosing Schedule: 0 Hours 4 Hours 8 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 240 mg/m 2 240 mg/m 2 Intravenous and Oral Dosing Schedule: 0 Hours 2 Hours 6 Hours Ifosfamide 1.2 g/m 2 -- -- MESNEX injection 240 mg/m 2 -- -- MESNEX tablets -- 480 mg/m 2 480 mg/m 2 Maintain sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria.
Source: US FDA prescribing information
MESNEX is contraindicated in patients known to be hypersensitive to mesna or to any of the excipients. Known hypersensitivity to mesna or to any of the excipients, including benzyl alcohol.
Source: US FDA prescribing information
Hypersensitivity reactions: Anaphylactic reactions have been reported. Less severe hypersensitivity reactions may also occur. Monitor patients. If a reaction occurs, discontinue MESNEX and provide supportive care. Dermatologic toxicity: Skin rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis have occurred. Skin rash, urticaria, and angioedema have also been seen. Monitor patients. Benzyl alcohol toxicity: Serious and fatal adverse reactions can occur in premature neonates and low-birth weight infants treated with benzyl alcohol-preserved drugs, including MESNEX injection. Avoid use in premature neonates and low-birth weight infants. Laboratory test alterations: False positive tests for urinary ketones and interference with enzymatic CPK activity tests have been seen.
Source: US FDA prescribing information
The following are discussed in more detail in other sections of the labeling. Hypersensitivity Reactions Dermatological Toxicity Benzyl Alcohol Toxicity Laboratory Test Interferences Use in Patients with a History of Adverse Reactions to Thiol Compounds The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.
Source: US FDA prescribing information
No clinical drug interaction studies have been conducted with MESNEX.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) If MESNEX is co-administered with ifosfamide, refer to the ifosfamide prescribing information for safe handling instructions. MESNEX (mesna) tablets NDC 67108-3565-9 400 mg scored tablets packaged in box of 10 tablets Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F)
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Mesna, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Mesna 1000 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Mesnex 1000 mg/10 mL injectionIntravenous | Baxter Healthcare | US FDA | Available on request |
| Mesna 400 mg tabletOralGeneric name | — | US FDA | Available on request |
| Mesnex 400 mg tabletOral | Baxter Healthcare | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 December 1988 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 4 presentations of Mesna and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Mesna, including Mesnex.
Yes. The US FDA first approved Mesna on 30 December 1988, according to Drugs@FDA.
No listed presentation of Mesna is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Mesna is classified under ATC code R05CB05 (Mesna).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.